SWAN: Blitzscaling the early detection of skin cancer
Swan offers rapid, full-body dermoscopic skin cancer detection using advanced AI and imaging technologies, enhancing early diagnosis and treatment accessibility for all stakeholders.
Projectdetails
Introduction
Swan is a breakthrough solution to the enduring problem of detecting skin cancer early. For the first time, Swan enables full-body scanning at dermoscopic resolution and in less than 3 minutes to the benefit of all stakeholders: patients, physicians, hospitals, and payers.
Key Features
The solution captures key data that dermatologists acutely need for early diagnosis and brings breakthrough AI triage assistance to flag concerning lesions.
Benefits
Significant medical time is saved in the process and for patients, the impact is:
- Faster access to treatment when needed
- Fewer unnecessary biopsies
- Peace of mind
Technology
The solution combines hardware and software and is at the crossroads of cutting-edge, patented technologies in:
- Real-time 3D human avatar generation
- Advanced robotic control
- Image processing
- AI classification of lesions
Ambition
Our ambition is to make best-in-class skin cancer screening accessible to everyone, everywhere and finally help dermatology make a quantum leap forward.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.500.000 |
Totale projectbegroting | € 3.920.366 |
Tijdlijn
Startdatum | 1-7-2022 |
Einddatum | 31-12-2024 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- SQUAREMINDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Pioneering diagnostics in dermatology and cancerDermagnostix aims to enhance dermatological diagnostics with a rapid, automated platform for precise molecular testing, reducing misdiagnoses and improving patient care. | EIC Accelerator | € 2.499.000 | 2022 | Details |
Real-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgeryThericon is developing an rMSI platform to enhance endoscopic cancer surgery by providing multi-parametric imaging for better tissue differentiation and reducing cancer recurrence, seeking funding for market launch in 2024. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Empowering Radiologists in Cancer Diagnostics with Artificial IntelligenceBetter Medicine AI automates repetitive tasks in cancer CT scan analysis, reducing radiologist workload by 40-60% to improve diagnostic accuracy and address the radiologist shortage. | EIC Accelerator | € 2.499.875 | 2024 | Details |
Pioneering diagnostics in dermatology and cancer
Dermagnostix aims to enhance dermatological diagnostics with a rapid, automated platform for precise molecular testing, reducing misdiagnoses and improving patient care.
Real-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgery
Thericon is developing an rMSI platform to enhance endoscopic cancer surgery by providing multi-parametric imaging for better tissue differentiation and reducing cancer recurrence, seeking funding for market launch in 2024.
Empowering Radiologists in Cancer Diagnostics with Artificial Intelligence
Better Medicine AI automates repetitive tasks in cancer CT scan analysis, reducing radiologist workload by 40-60% to improve diagnostic accuracy and address the radiologist shortage.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Digital Skintyping Platform based on dermoscopy & AII-Parse ontwikkelt een digitaal platform dat AI gebruikt om huidtype te analyseren via dermatoscoopbeelden, met als doel het risico op huidkanker te verminderen en monitoring te verbeteren. | Mkb-innovati... | € 18.888 | 2022 | Details |
SkinSight360SkinSight360 onderzoekt de haalbaarheid van AI-gedreven dermatologische zorg en verbetert de communicatie tussen patiënten en dermatologen. | Mkb-innovati... | € 20.000 | 2024 | Details |
MUlti-spectral Scattering matrix for Enhanced skin imagingThe ERC REMINISCENCE project developed the DeepInsight microscope, enabling advanced non-invasive 3D imaging for early melanoma detection and skin disease analysis, with plans for commercialization. | ERC Proof of... | € 150.000 | 2024 | Details |
Advancing stroke care with cutting-edge ultrasound biomarkers for Neurocritical CareResolve Stroke aims to enhance ultrasound imaging with the SYLVER system to improve stroke diagnosis and management through innovative biomarkers, making timely detection more accessible and effective. | EIC Transition | € 2.493.436 | 2025 | Details |
Accurate quantification of neurologic disease over timeThe project aims to develop CHRONOS, an AI-driven diagnostic tool using synthetic biomaps to enable earlier and more accurate detection of brain tumors, facilitating timely clinical decisions. | ERC Proof of... | € 150.000 | 2025 | Details |
Digital Skintyping Platform based on dermoscopy & AI
I-Parse ontwikkelt een digitaal platform dat AI gebruikt om huidtype te analyseren via dermatoscoopbeelden, met als doel het risico op huidkanker te verminderen en monitoring te verbeteren.
SkinSight360
SkinSight360 onderzoekt de haalbaarheid van AI-gedreven dermatologische zorg en verbetert de communicatie tussen patiënten en dermatologen.
MUlti-spectral Scattering matrix for Enhanced skin imaging
The ERC REMINISCENCE project developed the DeepInsight microscope, enabling advanced non-invasive 3D imaging for early melanoma detection and skin disease analysis, with plans for commercialization.
Advancing stroke care with cutting-edge ultrasound biomarkers for Neurocritical Care
Resolve Stroke aims to enhance ultrasound imaging with the SYLVER system to improve stroke diagnosis and management through innovative biomarkers, making timely detection more accessible and effective.
Accurate quantification of neurologic disease over time
The project aims to develop CHRONOS, an AI-driven diagnostic tool using synthetic biomaps to enable earlier and more accurate detection of brain tumors, facilitating timely clinical decisions.